Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.

Tsai HT, Penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL.

Urology. 2013 Aug;82(2):327-33. doi: 10.1016/j.urology.2013.01.078.

2.

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.

Ku JY, Lee JZ, Ha HK.

Korean J Urol. 2015 Oct;56(10):689-94. doi: 10.4111/kju.2015.56.10.689. Epub 2015 Oct 13.

3.

Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.

Dason S, Allard CB, Wang JG, Hoogenes J, Shayegan B.

Can J Urol. 2014 Apr;21(2 Supp 1):28-36. Review.

4.

Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.

Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, Fradet V, Turgeon AF.

JAMA Oncol. 2015 Dec;1(9):1261-9. doi: 10.1001/jamaoncol.2015.2895. Review.

PMID:
26378418
5.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
6.

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.

Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, Bretas FF.

BMC Urol. 2014 Jan 25;14:9. doi: 10.1186/1471-2490-14-9. Review.

7.

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK.

JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745.

PMID:
22147380
8.

Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.

Brungs D, Chen J, Masson P, Epstein RJ.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):105-11. doi: 10.1038/pcan.2014.10. Epub 2014 Apr 1. Review.

PMID:
24686773
9.

Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.

Parikh RA, Pascal LE, Davies BJ, Wang Z.

Asian J Androl. 2014 Jul-Aug;16(4):505-10. doi: 10.4103/1008-682X.125410. Review.

10.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
11.

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.

Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21.

PMID:
19249153
13.

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.

Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.

Ann Intern Med. 2000 Apr 4;132(7):566-77. Erratum in: Ann Intern Med. 2005 Nov 15;143(10):764-5.

PMID:
10744594
14.

Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer.

Klotz L.

Curr Urol Rep. 2013 Jun;14(3):159-67. doi: 10.1007/s11934-013-0325-x. Review.

PMID:
23700095
15.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
16.

Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.

Niraula S, Le LW, Tannock IF.

J Clin Oncol. 2013 Jun 1;31(16):2029-36. doi: 10.1200/JCO.2012.46.5492. Epub 2013 Apr 29. Review.

PMID:
23630216
17.

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group.

J Urol. 2008 Sep;180(3):915-9; discussion 919-20. doi: 10.1016/j.juro.2008.05.009. Epub 2008 Jul 17.

PMID:
18635219
18.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
19.

Intermittent versus continuous androgen suppression for prostatic cancer.

Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005009. Review.

PMID:
17943832
20.

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

J Urol. 2012 Jun;187(6):2074-81. doi: 10.1016/j.juro.2012.01.122. Epub 2012 Apr 11.

PMID:
22498230
Items per page

Supplemental Content

Write to the Help Desk